Hepatitis B reactivation after chemoimmunotherapy: screen before treatment

Hepatitis B reactivation after chemoimmunotherapy: screen before treatment

Laboratory investigations showed a raised white blood cell count of 916 000 × 109 per L. He was diagnosed with chronic lymphocytic leukaemia and started on fludarabine, cyclophosphamide, and rituximab. [...]investigations found the patient to be positive for HBsAg and anti-HBc, and his blood concent...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) Vol. 397; no. 10273; p. 510
Main Authors: Hwang, Jessica P, Ferrajoli, Alessandra, Lok, Anna S
Format: Journal Article
Language:English
Published: England Elsevier Ltd 06-02-2021
Elsevier Limited
Subjects:
Aged
Alanine Transaminase - blood
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antiviral Agents - administration & dosage
Blood levels
Chronic lymphocytic leukemia
Cyclophosphamide
Deoxyribonucleic acid
Dietary supplements
DNA
Fludarabine
Guanine - administration & dosage
Guanine - analogs & derivatives
Hepatitis
Hepatitis B
Hepatitis B - diagnosis
Hepatitis B - drug therapy
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Humans
Immunotherapy
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukocytes
Monoclonal antibodies
Patients
Recurrence
Research funding
Rituximab
Rituximab - administration & dosage
Rituximab - adverse effects
Targeted cancer therapy
Virus Activation - drug effects
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Laboratory investigations showed a raised white blood cell count of 916 000 × 109 per L. He was diagnosed with chronic lymphocytic leukaemia and started on fludarabine, cyclophosphamide, and rituximab. [...]investigations found the patient to be positive for HBsAg and anti-HBc, and his blood concentration of hepatitis B virus (HBV) DNA was greater than 170 000 000 IU/mL. Declaration of interests ASL served on the advisory board of Gilead; received research funding from Bristol-Myers Squibb, Gilead, and TARGET-RWE; and report consulting fees from Gilead, TARGET-RWE, and GlaxoSmithKline.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(21)00210-5